Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182890 | 0.94 | ALDH1A1 (0.51) | ALDH1A1HPGDAKR1C3CYP1A2CYP3A4 | |
| SCHEMBL182610 | 0.88 | ALDH1A1 (0.43) | ALDH1A1HPGDAKR1C3CYP1A2CYP3A4 | |
| SCHEMBL11142367 | 0.85 | ALDH1A1 (0.74) | ALDH1A1HPGDAKR1C3CYP1A2CYP3A4 | |
| SCHEMBL136476 | 0.79 | ALDH1A1 (0.67) | ALDH1A1HPGDAKR1C3CYP1A2CYP3A4 | |
| SCHEMBL1284684 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HPGDAKR1C3CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL7466356 | 0.78 | ALDH1A1 (0.65) | ALDH1A1HPGDAKR1C3CYP1A2CYP3A4 | |
| SCHEMBL78465 | 0.78 | ALDH1A1 (0.65) | ALDH1A1HPGDAKR1C3CYP1A2CYP3A4 | |
| SCHEMBL2337506 | 0.77 | ALDH1A1 (0.46) | ALDH1A1HPGDAKR1C3CYP1A2CYP3A4 | |
| SCHEMBL3138531 | 0.77 | ALDH1A1 (0.49) | ALDH1A1HPGDAKR1C3CYP1A2CYP3A4 | |
| SCHEMBL1656668 | 0.76 | ALDH1A1 (0.68) | ALDH1A1HPGDAKR1C3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 675 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230217-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | WO | claimed |
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | US | claimed |
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | claimed |
| EP-2780322-B1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | LIGAND PHARM INC (US) | 2018-05-16 | — | — | EP | claimed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | claimed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | claimed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | claimed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | claimed |
| EP-1891067-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2016-01-13 | — | — | EP | claimed |
| EP-1641762-A2 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | claimed |
| WO-2006004742-A2 | α, β-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION | JANSSEN PHARAMCEUTICA N.V. (BE) | 2006-01-12 | — | — | WO | claimed |
| JP-2006501194-A | — | — | 2006-01-12 | — | — | JP | claimed |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-05 | — | — | US | claimed |
| CN-1678587-A | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2005-10-05 | — | — | CN | claimed |
| EP-1525190-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-27 | — | — | EP | claimed |
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | JONES TODD K (US) | 2005-01-27 | — | — | US | claimed |
| WO-2005005393-A2 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-20 | — | — | WO | claimed |
| US-20040067983-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-08 | — | — | US | claimed |
| WO-2004007463-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-01-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | ALDH1A1 3435/4885HPGD 1678/4885AKR1C3 1162/4885 |
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | CCKAR, CCKBR, NPY1R | ALDH1A1 1572/4885HPGD 1690/4885AKR1C3 608/4885 |
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | MPO, SSB, SGMS2 | ALDH1A1 3079/4885HPGD 1442/4885AKR1C3 3054/4885 |
| US-20040067983-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | ALDH1A1 2402/4885HPGD 2028/4885AKR1C3 3066/4885 |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | CCKAR, CCKBR, FFAR1 | ALDH1A1 597/4885HPGD 618/4885AKR1C3 229/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | ALDH1A1 3435/4885HPGD 1678/4885AKR1C3 1162/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | ALDH1A1 3435/4885HPGD 1678/4885AKR1C3 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.